Result:Very Good· Market: Surged#Turnaround#Margin expansion#Broad based
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 29.30 | 0.7% | 54.3% |
| Total Income | 29.33 | 0.8% | 53.7% |
| Expenditure | 25.40 | 7.2% | 23.1% |
| PBT | 3.93 | 126.0% | 352.9% |
| Net Profit | 2.88 | 169.7% | 362.7% |
| OPM | 19.85% | 6.84pp | 18.64pp |
| NPM | 9.81% | 6.14pp | 15.55pp |
| EPS | 2.57 | 176.3% | 167.7% |
Pharma company delivered a genuine loss-to-profit turnaround with strong revenue growth (54.3% YoY) alongside sharp margin expansion (OPM 1.2%→19.9%), indicating core-business improvement rather than a one-off.
Informational and educational content only. Not investment advice.